GUMDROP : Phase I and II Study of Safety and Efficacy of Muscadine Plus, MPX, in Men with Prostate Cancer- A Randomized Dose-Finding Study of 2 Doses of MPX on Rising PSA following Initial Therapy

Created by Channing Paller, last modified on Apr 18, 2012

Description:

This study seeks to determine the safety and effectiveness of oral muscadine grape skin extract in slowing PSA doubling time. Eligible patients will have completed definitive local therapy (surgery, surgery w/ radiation, cryotherapy, radiation/brachytherapy) and has 3 rising PSAs at least one month apart over 12 months; testosterone = 150 ng/mL; NO METS.  Prior hormonal treatment must have been completed at least six months prior to start of study.

Link:

http://clinicaltrials.gov/ct2/show/NCT01317199

Site:

Johns Hopkins Hospital and Howard University Hospital

Principal Investigator:

Michael Carducci, M.D., Channing Paller, M.D., Sara Horton, M.D.
cpaller1@jhmi.edu